Treatment for Erectile Dysfunction

Although much has been learned in the physiology and molecular science of penile erection in recent decades, scientific discovery in this arena will predictably continue to be made. Science and technology are the cornerstone for new developments ranging from new pharmacotherapeutics to surgical innovations. Scientific discovery in the vascular biology and neurophysiology of penile erection will continue to take center stage with particular focus on molecular and cellular signaling pathways and growth factor mechanisms that may be exploited to produce the next generation of pharmacotherapeutics as well as gene, stem cell and regenerative therapies. Technologic advancements can also be expected to impact surgical procedures ranging from penile reconstructive to prosthetic to tissue replacement surgeries (e.g., penile transplantation). The field is positioned to bring forward single or combination therapies that characterize angiogenic, neurogenic, anti-fibrotic, anti-apoptotic, and other potential systems biologic approaches, which can be directed toward ED pathophysiologic conditions existing at either peripheral (i.e., genitalia) or central (i.e., brain and spinal cord) axis levels. A near-term practical scheme is to apply such treatments based on the systemic deficiency and severity extent of ED, utilizing a SDM process that is guided by the clinician after thorough discussion of all management considerations and incorporates intervention preferences of the man and his partner. Accordingly, a lesser presentation of vasculogenic ED may do well with as needed oral pharmacotherapy and lifestyle improvement whereas a more severe, tissue fibrotic presentation may require tissue regenerative and/or surgical interventions. In the future, diverse ED treatments likely will become available and can be offered in a highly effective, clinicopathologically targeted manner as linked with cause-specific ED-associated disease states. It is conceivable that the ED treatment armamentarium of the future will comprise therapies specific for diabetes-associated ED, for instance, that are distinct from those intended for neurogenic ED or severe vasculogenic ED. Improved diagnostics will have impact in this scope as well. Molecular profiling, genetic biomarkers and advanced imaging techniques may improve the specificity of treatment for each man and usher in an era of "personalized medicine" for ED.

Treatment Options for Erectile Dysfunction (ED)

The magnitude of average increased effects with increased doses is small and often not clinically significant (e.g., a one or two point increase on the IIEF-EF). IIEF-EF data for trials of sildenafil, tadalafil, and vardenafil that used fixed doses are below (insufficient data for avanafil). On demand dosing vs. daily dosing for tadalafil appears to produce the same level of efficacy. Note that daily dosing trials generally used lower doses than did on demand trials.

Extracorporeal Shockwave Therapy (ESWT)

Trials of sildenafil and avanafil used only on demand dosing. Data from trials that evaluated men from the general ED population are below. Tadalafil was the only medication for which there were substantial tadalista 2 5 on demand vs. daily dosing studies. Most AEs follow a dose-response pattern such that men in active treatment arms reported statistically significantly higher rates of AEs than did men in placebo arms and the percentage of men reporting a particular AE increased as dose increases.

4.3 Low-intensity extracorporeal shock wave therapy (Li-ESWT)

Within individual studies, however, the differences between dose groups were usually not statistically significantly different. Data from studies of men in the general ED population that administered medications at fixed doses (i.e., did not allow the patient to titrate dose up or down) are below. When means for the general and four special populations (men with diabetes, with BPH/LUTS, post-RP, or post-RT) for which there are substantial data were examined, it appears that men post-RP and men post-RT reported substantially higher rates of AEs than did men in the general ED population. Whether men who have had prostate cancer treatment are more likely to experience AEs or are more likely to report AEs is not clear. Men post-RP reported higher rates of AEs in response to sildenafil than in response to other PDE5s. Current interventions for ED are focused on symptomatic benefit. For example, although oral PDE5i were a major therapeutic breakthrough and now constitute a mainstay of ED management, these medications only mitigate symptoms rather than curing the underlying condition. Therapies with less restrictive, non-repetitive efficacy are greatly needed. The ultimate goal of ED management is to restore physiologically intact and natural erectile function. Durable and clinically significant improvement in erectile function is a less optimal but flibanserin still desirable goal if total recovery is not an option. Improvements in our ability to definitively manage ED will likely contribute to better life satisfaction and superior overall health outcomes. PDE5i have similar efficacy in the general ED population. Examination of data reported by trials that evaluated PDE5i revealed that these medications had similar efficacy among men in the general ED population, defined as men with a variety of underlying conditions that potentially contributed to ED symptoms.

Lifestyle Factor	Recommendations	Benefits
Smoking	Quit smoking	Improves blood flow, reduces risk of vascular disease
Physical Activity	Regular exercise (e.g., 30 min/day)	Enhances circulation, boosts testosterone levels
Diet	Mediterranean diet, low saturated fats	Reduces cardiovascular risk, improves vascular health
Alcohol Consumption	Limit or avoid alcohol intake	Prevents interference with erectile function

This pattern was evident when raw data were examined [see International Index of Erectile Function-Erectile Function (IIEF-EF) subscale table in guideline] as well as when the subset of data that could be meta-analyzed were pooled. The same patterns can be seen in the graph below that plots mean IIEF-EF baseline scores and mean post-treatment scores for each study by medication (symbols above the diagonal line reflect increased scores from baseline to post-treatment.

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	150mg	270 + 10 Pills	326.61€ 311.06€	Buy
Kamagra Oral Jelly	100 mg	21 Sachets	95.92€ 91.35€	Buy
Viagra Generic	150mg	20 Pills	55.02€ 52.40€	Buy
Kamagra Oral Jelly	100 mg	10 Sachets	54.55€ 51.95€	Buy
Levitra Original	20mg	120 + 8 Pills	528.19€ 503.04€	Buy
Levitra Professional	20mg	360 + 6 Pills	914.63€ 871.08€	Buy
Kamagra Oral Jelly	100mg	30 + 5 Sachets	136.20€ 129.71€	Buy
Viagra Original	100mg	14 + 2 Pills	89.03€ 84.79€	Buy
Levitra Generic	60mg	10 Pills	47.42€ 45.16€	Buy
Levitra Generic	40mg	60 + 4 Pills	162.37€ 154.64€	Buy
Cialis Generic	40mg	20 Pills	59.47€ 56.64€	Buy

Active treatment groups generally cluster above the placebo groups without clear separation among medications.1 Similar patterns are evident for other measures. Data from the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) are below; mean satisfaction scores (possible range 0 to 100) are similar across active medications (limited data available for tadalafil and vardenafil). The same pattern is evident for the Sexual Encounter Profile (SEP) question 2 ("Were you able to insert your penis into your partner's vagina?") and question 3 ("Did your erection last long enough for you to have successful intercourse?"). The percentages of men who respond "yes" are relatively similar across active medications (limited data are available for avanafil). A subgroup of studies used global assessment questions (GAQ 1 and 2) or global efficacy questions (GEQ 1 and 2).

4 Physical therapy of ED

Although much has been learned in the physiology and molecular science of penile erection in recent decades, scientific discovery in this arena will predictably continue to be made. Science and technology are the cornerstone for new developments ranging from new pharmacotherapeutics to surgical innovations. Scientific discovery in the vascular biology and neurophysiology of penile erection will continue to take center stage with particular focus on molecular and cellular signaling pathways and growth factor mechanisms that may be exploited to produce the next generation of pharmacotherapeutics as well as gene, stem cell and regenerative therapies. Technologic advancements can also be expected to impact surgical procedures ranging from penile reconstructive to prosthetic to tissue replacement surgeries (e.g., penile transplantation). The field is positioned to bring forward single or combination therapies that characterize angiogenic, neurogenic, anti-fibrotic, anti-apoptotic, and other potential systems biologic approaches, which can be directed toward ED pathophysiologic conditions existing at either peripheral (i.e., genitalia) or central (i.e., brain and spinal cord) axis levels.

What to expect from your doctor

A near-term practical scheme is to apply such treatments based on the systemic deficiency and severity extent of ED, utilizing a SDM process that is guided by the clinician after thorough discussion of all management considerations and incorporates intervention preferences of the man and his partner. Accordingly, a lesser presentation of vasculogenic ED may do well with as needed oral pharmacotherapy and lifestyle improvement whereas a more severe, tissue fibrotic presentation may require tissue regenerative and/or surgical interventions. In the future, diverse ED treatments likely will become available and can be offered in a highly effective, clinicopathologically targeted manner as linked with cause-specific ED-associated disease states. It is conceivable that the ED treatment armamentarium of the future will comprise therapies specific for diabetes-associated ED, for instance, that are distinct from those intended for neurogenic ED or severe vasculogenic ED. Improved diagnostics will have impact in this scope as well.

A Visual Guide to Erectile Dysfunction

Molecular profiling, genetic biomarkers and advanced imaging techniques may improve the specificity of treatment for each man and usher in an era of "personalized medicine" for ED. Current interventions for ED are focused on symptomatic benefit. For example, although oral PDE5i were a major therapeutic breakthrough and now constitute a mainstay of ED management, these medications only mitigate symptoms rather than curing the underlying condition. Therapies with less restrictive, non-repetitive efficacy are greatly needed. The ultimate goal of ED management is to restore physiologically intact and natural erectile function. The phrasing of the questions differs, but essentially question 1 asks whether the study medication has improved erections and question 2 asks whether, if the treatment has improved a man's erections, has his ability to engage in sexual activity improved. Again, there are no clear differences across medications (limited data for avanafil). Dose-response effects across PDE5i medications are small and non-linear (i.e., doubling the dose does not double the effect). Higher doses may produce higher average effects but dose groups generally were not statistically significantly different unless comparing extremely low doses to extremely high doses. The magnitude of average increased effects with increased doses is small and often not clinically significant (e.g., a one or two point increase on the IIEF-EF). IIEF-EF data for trials of sildenafil, tadalafil, and vardenafil that used fixed doses are below (insufficient data for avanafil). On demand dosing vs. daily dosing for tadalafil appears to produce the same level of efficacy. Note that daily dosing trials generally used lower doses than did on demand trials. Trials of sildenafil and avanafil used only on demand dosing.

• Gene therapy research
• Stem cell treatments
• Nanotechnology applications
• Future oral medications
• Clinical trials for new drugs
• Bioengineered implants
• Regenerative medicine
• Gene editing possibilities
• Revolutionary device prototypes
• Access to experimental treatments
• Research funding and development

Data from trials that evaluated men from the general ED population are below. Tadalafil was the only medication for which there were substantial tadalista 2 5 on demand vs. daily dosing studies. Most AEs follow a dose-response pattern such that men in active treatment arms reported statistically significantly higher rates of AEs than did men in placebo arms and the percentage of men reporting a particular AE increased as dose increases. Within individual studies, however, the differences between dose groups were usually not statistically significantly different.

Meet Our Patients

Durable and clinically significant improvement in erectile function is a less optimal but flibanserin still desirable goal if total recovery is not an option. Improvements in our ability to definitively manage ED will likely contribute to better life satisfaction and superior overall health outcomes. PDE5i have similar efficacy in the general ED population. Examination of data reported by trials that evaluated PDE5i revealed that these medications had similar efficacy among men in the general ED population, defined as men with a variety of underlying conditions that potentially contributed to ED symptoms. This pattern was evident when raw data were examined [see International Index of Erectile Function-Erectile Function (IIEF-EF) subscale table in guideline] as well as when the subset of data that could be meta-analyzed were pooled.

Dana Alan Ohl, MD

The same patterns can be seen in the graph below that plots mean IIEF-EF baseline scores and mean post-treatment scores for each study by medication (symbols above the diagonal line reflect increased scores from baseline to post-treatment. Active treatment groups generally cluster above the placebo groups without clear separation among medications.1 Similar patterns are evident for other measures. Data from the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) are below; mean satisfaction scores (possible range 0 to 100) are similar across active medications (limited data available for tadalafil and vardenafil). The same pattern is evident for the Sexual Encounter Profile (SEP) question 2 ("Were you able to insert your penis into your partner's vagina?") and question 3 ("Did your erection last long enough for you to have successful intercourse?"). The percentages of men who respond "yes" are relatively similar across active medications (limited data are available for avanafil).

ED Treatment Overview

A subgroup of studies used global assessment questions (GAQ 1 and 2) or global efficacy questions (GEQ 1 and 2). The phrasing of the questions differs, but essentially question 1 asks whether the study medication has improved erections and question 2 asks whether, if the treatment has improved a man's erections, has his ability to engage in sexual activity improved. Again, there are no clear differences across medications (limited data for avanafil). Dose-response effects across PDE5i medications are small and non-linear (i.e., doubling the dose does not double the effect). Higher doses may produce higher average effects but dose groups generally were not statistically significantly different unless comparing extremely low doses to extremely high doses. Data from studies of men in the general ED population that administered medications at fixed doses (i.e., did not allow the patient to titrate dose up or down) are below. When means for the general and four special populations (men with diabetes, with BPH/LUTS, post-RP, or post-RT) for which there are substantial data were examined, it appears that men post-RP and men post-RT reported substantially higher rates of AEs than did men in the general ED population. Whether men who have had prostate cancer treatment are more likely to experience AEs or are more likely to report AEs is not clear.

Psychological counseling

Funding of the Panel was provided by the AUA. Panel members received no remuneration for their work. Each member of the Panel provides an ongoing conflict of interest disclosure to the AUA. While these guidelines do not necessarily establish the standard of care, AUA seeks to recommend and to encourage compliance by practitioners with current best practices related to the condition being treated. Men post-RP reported higher rates of AEs in response to sildenafil than in response to other PDE5s.

Tip	Description	Expected Benefit
Maintain a healthy weight	Reduce obesity-related vascular risks	Improves overall circulation
Manage stress	Use meditation, yoga, or relaxation techniques	Reduces psychological barriers
Regular exercise	Boosts testosterone and improves blood flow	Enhances erectile function
Sleep well	Ensures hormonal balance and vascular health	Improves libido and performance

Men post-RT reported high rates of AEs across PDE5s and in placebo groups.

• Some men find relief through natural remedies, but evidence may be limited.
• Erectile dysfunction can be an early warning sign of cardiovascular disease.
• Lifestyle counseling is often part of comprehensive ED management.
• Regular exercise improves overall endothelial function.
• Medications like PDE5 inhibitors are most effective when taken properly.
• Psychological therapies are effective for ED with psychological causes.
• Surgery is considered when pharmacological and non-invasive options are ineffective.

The high rates of AEs reported by men in placebo groups suggest that men post-RT may have heightened sensitivity to body sensations and may have unmet needs for psychosocial support. These patterns can be seen in the table below (AEs for which there were 1 or 2 study arms are omitted); see cells in bold.

Premature Ejaculation (PE)

Men post-RT reported high rates of AEs across PDE5s and in placebo groups. The high rates of AEs reported by men in placebo groups suggest that men post-RT may have heightened sensitivity to body sensations and may have unmet needs for psychosocial support. These patterns can be seen in the table below (AEs for which there were 1 or 2 study arms are omitted); see cells in bold. Appendix B2 – Guideline Statement 16: Intracavernosal injection (ICI) data Commonly reported adverse events in extracted ICI studies: Appendix B3– Guideline Statement 18: Penile prosthesis data Patient and partner satisfaction data: Appendix B4 – Guideline Statement 21: Penile arterial reconstruction data Complete, partial, and non-response rates to surgery: Below are those data; for studies that reported response rates at different durations post-surgery, the latest duration was used. Appendix B5 – Guideline Statement 22: Penile venous surgery data Complete, partial, and non-response rates to surgery: The pattern of declining positive response rates over time can be seen in the scatterplot below which plots complete and partial responder rates by follow-up duration.

ED and Psychological Factors

The exception to this trend is Hsu, Chen (2010) who reported that 85.6% of 167 Taiwanese men at 92.4 mos of follow-up were complete responders to venous ligation surgery[926]. These men had no comorbidities at the time of surgery. The procedure involved stripping and ligation of the deep dorsal, emissary, and cavernosal veins as well as ligation of the para-arterial veins; some men also had ligation of the crural veins. Overall, there was considerable variability regarding response rates. Below are those data; for studies that reported response rates at different durations post-surgery, the latest duration was used.

COVID-19 and Erectile Dysfunction: Fact or Fiction?

This document was written by the Erectile Dysfunction Guideline Panel of the American Urological Association Education and Research, Inc., which was created in 2016. The Practice Guidelines Committee (PGC) of the AUA selected the committee chair. Panel members were selected by the chair. Membership of the Panel included specialists in urology, family medicine, and psychology with specific expertise on this disorder. The mission of the Panel was to develop recommendations that are analysis-based or consensus-based, depending on Panel processes and available data, for optimal clinical practices in the treatment of muscle-invasive bladder cancer. Appendix B2 – Guideline Statement 16: Intracavernosal injection (ICI) data Commonly reported adverse events in extracted ICI studies: Appendix B3– Guideline Statement 18: Penile prosthesis data Patient and partner satisfaction data: Appendix B4 – Guideline Statement 21: Penile arterial reconstruction data Complete, partial, and non-response rates to surgery: Below are those data; for studies that reported response rates at different durations post-surgery, the latest duration was used. Appendix B5 – Guideline Statement 22: Penile venous surgery data Complete, partial, and non-response rates to surgery: The pattern of declining positive response rates over time can be seen in the scatterplot below which plots complete and partial responder rates by follow-up duration.

• Headache with PDE5i
• Vision changes or blurriness
• Muscle aches and back pain
• Nasal congestion
• Indigestion and heartburn
• Priapism warning signs
• Sudden hearing loss
• Priapism emergency care
• Stopping medication abruptly
• Allergic reactions to meds
• Long-term side effects

The exception to this trend is Hsu, Chen (2010) who reported that 85.6% of 167 Taiwanese men at 92.4 mos of follow-up were complete responders to venous ligation surgery[926]. These men had no comorbidities at the time of surgery. The procedure involved stripping and ligation of the deep dorsal, emissary, and cavernosal veins as well as ligation of the para-arterial veins; some men also had ligation of the crural veins.

Speak to your provider about ED

Overall, there was considerable variability regarding response rates. Below are those data; for studies that reported response rates at different durations post-surgery, the latest duration was used. This document was written by the Erectile Dysfunction Guideline Panel of the American Urological Association Education and Research, Inc., which was created in 2016. The Practice Guidelines Committee (PGC) of the AUA selected the committee chair. Panel members were selected by the chair.

Psychological Cause	Description	Treatment Options
Anxiety	Performance anxiety causing ED	Counseling, cognitive-behavioral therapy
Depression	Reduced libido and ED	Antidepressants, psychotherapy
Relationship issues	Communication problems affecting intimacy	Couples therapy
Stress	Chronic stress impairing vascular health	Relaxation techniques, mindfulness

Membership of the Panel included specialists in urology, family medicine, and psychology with specific expertise on this disorder. The mission of the Panel was to develop recommendations that are analysis-based or consensus-based, depending on Panel processes and available data, for optimal clinical practices in the treatment of muscle-invasive bladder cancer.

• Medications like PDE5 inhibitors improve erectile performance by increasing blood flow.
• Regular exercise enhances cardiovascular health, which is vital for erectile function.
• Managing stress and mental health issues can significantly improve ED symptoms.
• Alternative therapies such as acupuncture may provide relief for some men.
• Avoiding excessive alcohol consumption can help prevent or reduce ED symptoms.
• Addressing underlying health conditions like diabetes or hypertension is crucial.
• Communicating openly with partners can reduce performance anxiety and improve intimacy.

Funding of the Panel was provided by the AUA. Panel members received no remuneration for their work. Each member of the Panel provides an ongoing conflict of interest disclosure to the AUA. While these guidelines do not necessarily establish the standard of care, AUA seeks to recommend and to encourage compliance by practitioners with current best practices related to the condition being treated.